This company may still be operating, however this listing is no longer active. Find out why through their latest events.

TCR2 Therapeutics Crecimiento futuro

We currently don't have sufficient analyst coverage to forecast growth and revenue for TCR2 Therapeutics.

5.0%

Tasa de crecimiento de los beneficios

22.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	30.2%
Tasa de crecimiento de los ingresos	87.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	n/a

No hay actualizaciones

Previsiones de crecimiento de beneficios e ingresos

MUN:2K7 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	10	-169	-142	-131	5
12/31/2023	N/A	-149	-128	-123	7
12/31/2022	N/A	-127	-118	-114	8
6/30/2022	N/A	-115	-111	-93	N/A
3/31/2022	N/A	-107	-101	-89	N/A
12/31/2021	N/A	-100	-93	-82	N/A
9/30/2021	N/A	-91	-81	-72	N/A
6/30/2021	N/A	-81	-72	-63	N/A
3/31/2021	N/A	-73	-72	-64	N/A
12/31/2020	N/A	-67	-64	-57	N/A
9/30/2020	N/A	-61	-57	-54	N/A
6/30/2020	N/A	-58	-57	-53	N/A
3/31/2020	N/A	-53	-51	-47	N/A
12/31/2019	N/A	-97	-45	-41	N/A
9/30/2019	N/A	-96	-41	-37	N/A
6/30/2019	N/A	-100	-33	-32	N/A
3/31/2019	N/A	-107	-27	-27	N/A
12/31/2018	N/A	-62	-20	-19	N/A
9/30/2018	N/A	-55	-18	-17	N/A
12/31/2017	N/A	-15	-12	-12	N/A

Ingresos vs. Tasa de ahorro: 2K7 is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: 2K7 is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: 2K7 is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: 2K7 is forecast to have no revenue next year.

Ingresos de alto crecimiento: 2K7 is forecast to have no revenue next year.

ROE futura: Insufficient data to determine if 2K7's Return on Equity is forecast to be high in 3 years time